Cisplatin resistance remains an obstacle in oral cancer and the identification of potential protein biomarker is crucial for the improvement of cancer therapy. This thesis focuses on the role and regulation played by the protein, transglutaminase 2 (TGM2) in relation to cisplatin resistance in oral cancer-derived extracellular vesicles. Its expression and prognosis was first investigated through bioinformatic tools, followed by further examination into its relationship with oral squamous cell carcinoma cells and its extracellular vesicles with varied degree of cisplatin sensitivities.<p></p>